Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. - Wikidata - awgldk - TriplyDB

Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients.

Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients.

http://www.wikidata.org/entity/Q33412915

about

Antiplatelet and anticoagulant agents for preventing recurrence of peripheral vascular thrombosis in patients with Antiphospholipid syndrome Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay The role of the gut microbiota in the pathogenesis of antiphospholipid syndrome Neonatal outcome in pregnant patients with antiphospholipid syndrome.The challenge of bleeding in antiphospholipid antibody-positive patients.Circulating Immune Complexes of IgA Bound to Beta 2 Glycoprotein are Strongly Associated with the Occurrence of Acute Thrombotic Events Thrombocytopenic syndromes in pregnancy.Disease flare patterns and predictors of systemic lupus erythematosus in a monocentric cohort of 423 Japanese patients during a long-term follow-up: The JUDE study.Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: a longitudinal study.Systemic lupus erythematosus and thrombosis.The Effects of NF-κB and c-Jun/AP-1 on the Expression of Prothrombotic and Proinflammatory Molecules Induced by Anti-β2GPI in Mouse Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant.The antiphospholipid syndrome: still an enigma Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy Soluble analog of ApoER2 targeting beta2-glycoprotein I in immune complexes counteracts hypertension in lupus-prone mice with spontaneous antiphospholipid syndrome Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.Organ Damage and Quality of Life in Antiphospholipid Syndrome.Effect of ethnicity on clinical presentation and risk of antiphospholipid syndrome in Roma and Caucasian patients with systemic lupus erythematosus: a multicenter cross-sectional study.Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome.Musculoskeletal manifestations of the antiphospholipid syndrome.Anti-ApoA-1 IgG serum levels predict worse poststroke outcomes.Treatment of catastrophic antiphospholipid syndrome Direct oral anticoagulants: an alternative treatment for thrombotic antiphospholipid syndrome?Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment.Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome.Incidence of thromboembolic events in asymptomatic carriers of IgA anti ß2 glycoprotein-I antibodies.Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS).Dimerized Domain V of Beta2-Glycoprotein I Is Sufficient to Upregulate Procoagulant Activity in PMA-Treated U937 Monocytes and Require Intact Residues in Two Phospholipid-Binding Loops.Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review.Surgical Interventions for Organ and Limb Ischemia Associated With Primary and Secondary Antiphospholipid Antibody Syndrome With Arterial Involvement.Clinical characteristics and thrombosis outcomes of paediatric antiphospholipid syndrome: analysis of 58 patients.Diagnosis and management of the antiphospholipid syndrome.Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances.The impact of antibody profile in thrombosis associated with primary antiphospholipid syndrome.Vascular Manifestations in Antiphospholipid Syndrome (APS): Is APS a Thrombophilia or a Vasculopathy?Antiphospholipid syndrome and IgA anti-beta2-glycoprotein I antibodies: when Cinderella becomes a princess.Lymphocyte Disturbances in Primary Antiphospholipid Syndrome and Application to Venous Thromboembolism Follow-Up.Antiphospholipid syndrome in Sarawak: real world experience in a developing country.Antiphospholipid antibodies induce thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium.Maternal and fetal outcome in women with antiphospholipid syndrome: a three-year observational study.

P2860

Q24185813-7311EBF3-603B-449E-90B7-79E635887480 Q26739950-275B9A05-BF68-4741-AC34-193A8AA9BCA5 Q26866133-2ADB3245-3226-44B5-A838-570A8C310132 Q33418245-10D6A9B2-4B69-4255-BABA-026310C05FEE Q33419972-32587B18-7935-464F-8333-0F27FB5A283F Q33431396-3ADBFE2A-B2E0-45BC-A7BC-837EA4B53D39 Q33434497-F9957020-9CF0-43B8-A85C-3C066E32529A Q33434719-9FC0AA51-E772-45CF-82A3-82DC250437AE Q33443108-FE7A1F5C-D2BB-43DB-9E65-4DB31A3337F7 Q35530248-F9217B47-2755-4C4F-8F52-0AF6BA255DB0 Q35909733-EDB7DD89-13CF-4084-B262-660C6E1ABBFE Q36303250-874B4C62-31B7-4406-A21D-82BDFE3ACA09 Q36928593-05E619BB-AB07-45FE-B179-721571429543 Q37137892-F3320C60-A2C6-4907-982D-E8157B950BE9 Q37204282-F6C5876A-9D25-467E-9EF6-2BABD8AD2514 Q38657043-69CC4B9B-319A-42C2-9DB3-B50C7C210C40 Q38697342-69E8DC91-831E-40F9-9680-BCAE23C21590 Q38736953-E1C19341-73E6-4F76-8C53-AC3F229ABDBA Q38753510-DFF19F06-1262-4DFA-98B3-F1D80C4F90F8 Q38753531-CCB3F77B-D748-41E1-9818-5FFE34C01905 Q38753862-BA2705DA-3968-4BC6-AB50-1875F90413C2 Q38755260-EC2B0A26-C804-458D-9454-F29AF3760666 Q38868618-F35928C9-567E-4563-BE3F-CF2B44055A98 Q39449741-4FA3C847-66BC-49F3-B6CA-25928EEF87F4 Q39608521-FC59D451-AACC-443A-A774-7F020856C236 Q40115024-776C22AB-75C3-4018-BD88-BED2A6B37787 Q40323287-B513CB5A-83D0-4641-8CA4-A557E89AE32A Q41103646-72DA5B6C-762C-4EC3-A6CF-C6ECF2748D99 Q47372819-DCC02283-30AD-4B06-9F8F-CB6479BAD81A Q47636314-C40DD3E8-D158-4FD6-8F43-4ED4D34AE81E Q47685633-8CEEB677-EE41-4047-86AF-51C67B012576 Q47982275-7A45D2F8-0BA0-49E0-9312-FD5829536428 Q47998109-92F7025E-377C-4C98-A1E3-23F02B9B7052 Q48005192-7FA4A75D-BAE6-4151-A13C-1AE33F444B60 Q48035289-8B2FC812-B1B2-4832-97D7-3ACF62D5196E Q48567974-C4451F09-C4EC-4485-AD68-B294678B9005 Q50640109-3AE14D7F-919E-4379-8B54-0AB010E482CD Q51140007-2600AFD0-BA94-446D-B420-459576710669 Q52368982-D4E40427-B8F8-4DC9-8765-5C989495ED72 Q53773313-F871F21E-6769-4CE9-9416-E4131A4110DC

P2860

Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients.

http://www.wikidata.org/entity/Q33412915

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Morbidity and mortality in the ...... ective study of 1000 patients.

@ast

Morbidity and mortality in the ...... ective study of 1000 patients.

@en

type

label

Morbidity and mortality in the ...... ective study of 1000 patients.

@ast

Morbidity and mortality in the ...... ective study of 1000 patients.

@en

prefLabel

Morbidity and mortality in the ...... ective study of 1000 patients.

@ast

Morbidity and mortality in the ...... ective study of 1000 patients.

@en

P1433

Q33412915-4FC783F5-DD2D-45CA-9B90-B3CD6E30AA7F

P1476

Q33412915-BE8DF685-DCCD-487D-9AF6-37C5F5C90232

P2093

Q33412915-0ADE0FB1-B6A0-40FC-9687-47D436B7F46D

Q33412915-1C3834A0-1135-490A-9004-2E35640F3852

Q33412915-370107C5-D328-40FB-9AF0-5A048B6317CF

Q33412915-37E95438-74BA-498C-9243-31044619309B

Q33412915-40F1819C-DE45-4E4C-A5CB-FD07B24F0D92

Q33412915-46988F15-37A7-4E98-B9B5-6B2B86AF14BC

Q33412915-4C752F32-7E9B-4391-8691-06FE4EAF7285

Q33412915-50C54034-59E7-47FE-9D39-67865E2FE554

Q33412915-5104EFCD-7CAC-44DA-8AD1-359B1BD551FC

Q33412915-52AD711D-8847-4ED3-A7CF-BAEF20023B05

P304

Q33412915-F48BEF04-C171-438E-82C4-F91333F3E6BC

P31

Q33412915-3B3F54F4-EDA9-44BD-9CB0-4A243E365355

P356

Q33412915-C66BAB03-F652-4C5B-87D0-4AEA3D9322D4

P407

Q33412915-C2DA749C-CFEE-4EBD-9D7C-FFA32D242DE7

P433

Q33412915-C63A7E1E-8C17-47CD-8BD5-A882EB82B048

P478

Q33412915-FD5D123E-FBAD-4F54-85B8-8882019B3826

P50

Q33412915-18DF84BA-A466-4971-AEC7-F34BAC1E814B

Q33412915-45CA8A33-9F06-4E47-95FE-115B4C0CDFAE

Q33412915-500B0115-7B40-4EEE-848B-3143101314D2

Q33412915-599C5C00-729F-4B38-864F-AB8EA1A50CAE

Q33412915-5DC3EDD8-5EC4-42FF-BD26-8F55D9094A8B

Q33412915-80098724-2754-4023-A69B-069114FCF451

Q33412915-9F5B7920-07D2-4ABF-8111-69B514E765B3

Q33412915-A49475E7-DFEF-4065-B68D-E3D5E695E613

Q33412915-AD4CD867-D8A7-47DC-9A0B-63040C7B0D79

Q33412915-D39B3EE0-7A80-410B-B701-D9C64338127A

P577

Q33412915-61F7DBD0-C446-4897-A5ED-646328B6BC39

P5875

Q33412915-E6E64207-2C20-440A-B260-8F65E2CF38B9

P698

Q33412915-57E090C6-6B53-46D6-B1E5-FE7FB4465672

P921

Q33412915-5BDC57E2-2F01-4FBE-9DF5-4625956F8544

P356

ANNRHEUMDIS-2013-204838

P1433

Annals of the Rheumatic Diseases

P1476

Morbidity and mortality in the ...... ective study of 1000 patients.

@en

P2093

E Hachulla

http://www.w3.org/2001/XMLSchema#string

E Nomikou

http://www.w3.org/2001/XMLSchema#string

E de Ramón

http://www.w3.org/2001/XMLSchema#string

Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies)

http://www.w3.org/2001/XMLSchema#string

F Bellisai

http://www.w3.org/2001/XMLSchema#string

F Houssiau

http://www.w3.org/2001/XMLSchema#string

G J Pons-Estel

http://www.w3.org/2001/XMLSchema#string

G Theodossiades

http://www.w3.org/2001/XMLSchema#string

I Quéré

http://www.w3.org/2001/XMLSchema#string

J-C Gris

http://www.w3.org/2001/XMLSchema#string

P304

1011-1018

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ANNRHEUMDIS-2013-204838

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P50

Yehuda Shoenfeld

Pier Luigi Meroni

Antonio Fernandez-Nebro

Carlos Vasconcelos

Gerard Espinosa

Munther A. Khamashta

Stefano Bombardieri

P577

2014-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46721777

http://www.w3.org/2001/XMLSchema#string

P698

24464962

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial